Fundraising Fox

Causaly

London · Founded 2017 · Delaware corporation · 10 known investors

causaly.com ↗

Causaly builds an agentic AI platform for life sciences R&D that retrieves and reasons over scientific evidence, using a scientific knowledge graph and specialized AI agents to support target identification, indication discovery, and regulatory evidence validation. It serves biomedical and pharmaceutical enterprises across the R&D pipeline, from early research through clinical development and post-market.

AI & Machine LearningBiotechHealthtechin /causaly
Causaly website preview

Founders & leadership

Causaly was founded in 2017 by Yiannis Kiachopoulos.

YKYiannis Kiachopoulos
Yiannis KiachopoulosinFounder
AS
Artur SaudabayevNamed on SEC filing
JK
Joannis KiahopoulosNamed on SEC filing

Board

MM
Marc MoensBoard director
GT
Georgios TziralisBoard director
CG
Carlos Gonzalez-CadenasinBoard directorInvestor at Index Ventures

Investors · 10

EBRD Venture Capital Investment ProgrammeLondon · $2.2M – $27M
EmergeLondon · $500K – $2.5Mvia Jan Lynn-Matern · inferred
Emerge EducationLondon · $500K – $2.5Mvia Jan Lynn-Matern · inferred
ICONIQSan Francisco
Index VenturesSan Francisco · $540K – $10.8M
Marathon Venture CapitalAthens · $250K – $1M
Pentech VenturesEdinburgh · $635K – $2.5M
SNÖ VenturesOslo · $540K – $1.6M
ICONIQ GrowthreportedSan Francisco
Visionaries ClubreportedBerlin · $900K

Reported raises · per SEC filings

Form D private placements

$83.2M disclosed across 5 rounds · 2018–2023

▶$53MraisedJul 2023 · 12 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Carlos Gonzalez-CadenasDirector
  • Joannis KiahopoulosExecutive Officer, Director
  • Artur SaudabayevExecutive Officer, Director
  • Marc MoensDirector
  • Georgios TziralisDirector
  • Caroline XieDirector
Offering amount
$60M
Amount sold
$53M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.7MraisedOct 2022 · 9 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Joannis KiahopoulosExecutive Officer, Director
  • Georgios TziralisDirector
  • Marc MoensDirector
  • Carlos Gonzalez-CadenasDirector
  • Artur SaudabayevExecutive Officer, Director
Offering amount
$10.1M
Amount sold
$7.7M
First sale
Oct 2022
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.5MraisedMay 2021 · 13 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Marc MoensDirector
  • Artur SaudabayevExecutive Officer, Director
  • Georgios TziralisDirector
  • Joannis KiahopoulosExecutive Officer, Director
  • Carlos Gonzalez-CadenasDirector
Offering amount
$16.5M
Amount sold
$16.5M
First sale
May 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.8MraisedNov 2019 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Georgios TziralisDirector
  • Marc MoensDirector
  • Artur SaudabayevExecutive Officer, Director
  • Joannis KiahopoulosExecutive Officer, Director
Offering amount
$4.8M
Amount sold
$4.8M
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedJul 2018 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Georgios TziralisDirector
  • Artur SaudabayevExecutive Officer, Director
  • Joannis KiahopoulosExecutive Officer, Director
Offering amount
$1.2M
Amount sold
$1.2M
First sale
Jul 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Causaly Raises $60M in Series B Funding to Catalyze AI-powered Preclinical Discovery - AIwirehpcwire.com · Jul 2023Causaly Raises $60M in Series B Fundingfinsmes.com · Jul 2023Causaly scores $60M to enhance AI platform for biomedical research | MobiHealthNewsmobihealthnews.com · Jul 2023Ex-J&J CEO Alex Gorsky joins $60M funding for Causaly's speed-reading drug discovery AIfiercebiotech.com · Jul 2023Causaly Raises $60m to Catalyze... | Index Venturesindexventures.com · Jul 2023Causaly, an AI platform for drug discovery and biomedical research, raises $60M | TechCrunchtechcrunch.com · Jul 2023Causaly raises $17M to accelerate biomedical researchcausaly.com · May 2021

Frequently asked questions

What does Causaly do?
Causaly builds an agentic AI platform for life sciences R&D that retrieves and reasons over scientific evidence, using a scientific knowledge graph and specialized AI agents to support target identification, indication discovery, and regulatory evidence validation. It serves biomedical and pharmaceutical enterprises across the R&D pipeline, from early research through clinical development and post-market.
Who founded Causaly?
Causaly was founded by Yiannis Kiachopoulos in 2017.
Who are Causaly's investors?
Causaly's investors include EBRD Venture Capital Investment Programme, Emerge, Emerge Education, ICONIQ, Index Ventures, Marathon Venture Capital, Pentech Ventures, SNÖ Ventures and 2 more.
How much funding has Causaly raised?
Causaly has disclosed $83.2M raised across 5 rounds.
Where is Causaly headquartered?
Causaly is headquartered in London.